Brought to you by 
Watson buys US rights to 3 Searle contraceptives for $120mm
13 Jul 1999
Executive Summary
Watson Pharmaceuticals (generics, niche drugs) subsidiary Watson Laboratories will acquire US rights to three oral contraceptive products, TriNorinyl, Norinyl and Brevicon from Monsanto subsidiary GD Searle & Co. for $120mm.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Watson buys US rights to 3 Searle contraceptives for $120mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice